Core Insights - The report titled "2025-2031 China Ginkgo Biloba Industry Deep Investigation and Prospect Trend Report" provides essential reference for decision-makers and investors in the Ginkgo Biloba industry [1][14] - The Ginkgo Biloba industry is characterized by its rich medicinal value and cultural significance, with applications in treating cardiovascular diseases and improving memory [8][13] Industry Overview - Ginkgo Biloba is derived from the dried leaves of the Ginkgo tree, known for its medicinal properties such as promoting blood circulation and reducing cholesterol [5][8] - The industry is expected to see significant growth, with an estimated market value of approximately 594.8 billion yuan by 2027 [8][9] Market Environment Analysis - The report utilizes various data collection methods, including annual reports from listed companies, manufacturer surveys, and expert validations, to ensure data accuracy [4] - The analysis reflects the current market status, trends, and dynamics, allowing industry participants to understand the Ginkgo Biloba industry's development [4] Economic Indicators - The Ginkgo Biloba industry is projected to reach a market scale of 61.76 billion yuan by 2027, driven by the increasing demand from the aging population [9][10] - The report includes a comprehensive analysis of economic indicators relevant to the Ginkgo Biloba industry from 2020 to 2024, covering production, sales, and profitability [18] Competitive Landscape - The report analyzes the competitive dynamics within the Ginkgo Biloba industry, including market concentration and competitive strategies of key players [6][24] - It highlights the competitive advantages of various companies operating in the Ginkgo Biloba sector [21][23] Future Trends and Investment Opportunities - The report forecasts the supply and demand for the Ginkgo Biloba industry from 2025 to 2031, identifying potential investment opportunities and risks [11][25] - It emphasizes the importance of strategic planning for companies looking to invest in the Ginkgo Biloba market [12][25]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 中國中藥控股有限公司 | | | 呈交日期: | 2025年10月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00570 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 5,035,801,852 | | 0 | | 5,035,801,852 | | 增加 / 減少 (-) | | | | ...

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 中國中藥控股有限公司 (Incorporated in Hong Kong with limited liability) （於香港註冊成立之有限公司） (Stock code 股份代號：570) Dear non-registered shareholder(s), China Traditional Chinese Medicine Holdings Co. Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication of the Company are available on the website of the Company at www.china-tcm.com.cn and the ...

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 中國中藥控股有限公司 (Incorporated in Hong Kong with limited liability) （於香港註冊成立之有限公司） (Stock code 股份代號：570) 30 September 2025 Dear registered shareholder(s), China Traditional Chinese Medicine Holdings Co. Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication of the Company are available on the website of the Company at www.china-tcm. ...

2025 2025 中期報告 Interim Report China Traditional Chinese Medicine Holdings Co. Limited 2025 Interim Report 2025 中期報告 中 國 中 藥 控 股 有 限 公 司 目錄 公司資料 2 管理層討論及分析 3 其他資料 25 中期簡明合併財務報表審閱報告 28 中期簡明合併損益及其他全面收益表 30 中期簡明合併財務狀況表 31 中期簡明合併權益變動表 33 中期簡明合併現金流量表 34 中期簡明合併財務資料附註 35 公司資料 董事會 執行董事 楊 軍先生 （主席） 李鴻堅先生 彭 力先生 非執行董事 劉海建先生 李向榮先生 祖 敬先生 許京輝女士 黃 灝先生 獨立非執行董事 謝 榮先生 余梓山先生 秦 嶺先生 李偉東先生 公司秘書 伍秀薇女士 審核委員會 謝 榮先生 （主席） 祖 敬先生 余梓山先生 秦 嶺先生 李偉東先生 薪酬與考核委員會 秦 嶺先生 （主席） 謝 榮先生 余梓山先生 李偉東先生 提名委員會 楊 軍先生 （主席） 李鴻堅先生 許京輝女士 謝 榮先生 余梓山先生 秦 嶺先生 李偉東先生 ...

Core Insights - The report by Zhiyan Consulting highlights a decline in China's traditional Chinese medicine (TCM) material imports and exports in July 2025, indicating potential challenges in the industry [1] Import and Export Data - In July 2025, China's TCM material imports totaled 18,300 tons, representing a year-on-year decrease of 10.1% [1] - The import value for the same period was $2.9 million, down 11.8% year-on-year [1] - Exports of TCM materials reached 10,000 tons in July 2025, showing a year-on-year increase of 1.7% [1] - However, the export value decreased to $6.5 million, reflecting a significant decline of 16.6% year-on-year [1] Industry Analysis - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in in-depth industry research and providing comprehensive consulting services [1] - The firm emphasizes its commitment to delivering quality services and market insights to empower investment decisions [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 中國中藥控股有限公司 | | | 呈交日期: | 2025年9月4日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00570 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 5,035,801,852 | | 0 | | 5,035,801,852 | | 增加 / 減少 (-) | | | | | ...

Group 1 - The core viewpoint of the news is that Tongjitang Pharmaceutical has signed agreements with China National Pharmaceutical Group and Wuhan Hongli for the construction of a purification project and procurement of wastewater pretreatment facilities for its alcohol extraction workshop, which is crucial for enhancing production capacity and quality of its core products [1][2] Group 2 - The agreements are significant components of the alcohol extraction workshop construction project, which is essential for supporting the production of Tongjitang Pharmaceutical's core products [2] - By entering into these agreements, the company aims to leverage the internal synergy of China National Pharmaceutical Group, reduce project costs, and improve overall efficiency [2] - China National Pharmaceutical Group possesses various construction and management qualifications, which were considered during the bidding process, leading to the decision to accept their proposal [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 570 有關醇提取車間建設項目－淨化工程施工協議及 污水預處理配套設備設施採購項目協議之關連交易 董事會宣佈，本公司之附屬公司同濟堂製藥於2025年9月1日簽訂下列協議（「該等協 議」）： - 1 - (1) 與國藥工程及武漢宏利簽訂醇提取車間建設項目－淨化工程施工協議：國藥工程 與武漢宏利為同濟堂製藥醇提取車間及其配套機房、罐區提供建築裝飾裝修工 程、給排水工程、暖通工程、電氣工程、工藝管道工程、熱力工程、自控工程、 不銹鋼器具、鋼平台、設備工程等施工。 (2) 與國藥工程簽訂醇提取車間建設項目－污水預處理配套設備設施採購項目協議： 國藥工程為同濟堂製藥醇提取車間建設項目提供污水預處理配套設備設施建設， 包括勘察、設計、工藝設備採購安裝及配套設施施工等。 上市規則之涵義 於本公告日期，國藥集 ...

Core Viewpoint - China Traditional Chinese Medicine (00570.HK) reported a significant decline in mid-term performance for the six months ending June 30, 2025, with revenue of approximately RMB 7.46 billion, a year-on-year decrease of 11.0% and a loss of RMB 142 million, marking a substantial drop in basic earnings per share to RMB -0.0214, down 151.1% from RMB 0.0419 in the same period last year [1][1][1] Revenue Performance - The decline in sales revenue is primarily attributed to the increased proportion of traditional Chinese medicine formula granules in the collective procurement business and intensified market competition [1][1][1] - The company is actively promoting structural optimization in its operations, focusing on the development of advantageous varieties and local products, while strategically reducing low-margin and high-risk businesses, which has contributed to the decrease in revenue [1][1][1] Business Strategy - The company has paused certain homogenized and non-competitive product lines and businesses within the traditional Chinese medicine health sector, leading to a further decline in revenue during the reporting period [1][1][1]